Dr. (Prof.) Vijay Patil is a distinguished medical oncologist with over 2 decades of clinical and research experience, specializing in the management of solid tumors and the development of next-generation cancer therapies. He has authored more than 777 peer-reviewed publications in leading international journals, including the Journal of Clinical Oncology, The Lancet Global Health, Oral Oncology, Cancer, Cancer Cell, and ASCO publications.
He completed his MBBS from Seth Gordhandas Sunderdas Medical College (GSMC) & KEM Hospital, Mumbai (2006), followed by an MD in Radiotherapy from PGIMER, Chandigarh (2009) with the Kataria Gold Medal, and earned his DM in Medical Oncology from Tata Memorial Centre, Mumbai, in 2013 with a Gold Medal.
Over the course of his career, Dr. (Prof.) Vijay Patil has cared for more than 12 lakhs patients and contributed to the development of new treatment approaches and clinical criteria in oncology. He has also played an active role in national and international clinical trials, helping to bring emerging therapies into practice.
His treatment experience spans:
• Chemotherapy – 5,00,000+ patients
• Metronomic Chemotherapy – 1,50,000+ patients
• Targeted Therapies – 1,00,000+ patients
• Immunotherapy – 10,000+ patients
• CAR T- cell Therapy – among the early adopters in India, involved in patient selection, administration, and follow-up care.
Through a combination of clinical experience and ongoing research, he continues to contribute to advancements in cancer treatment for patients across the country.
• Disease Focus: All Solid Tumors, Hematologic Malignancies, and Blood Disorders
Academic Appointments:
Professor, Medical Oncology
P.D. Hinduja Hospital, Mahim & Khar | 2022 – Present
Professor, Medical Oncology
Tata Memorial Hospital, Mumbai | 2020 – 2022
Associate Professor, Medical Oncology
Tata Memorial Hospital, Mumbai | 2017 – 2019
Assistant Professor, Medical Oncology
Tata Memorial Hospital, Mumbai | 2015 – 2016
Assistant Professor, Medical Oncology
Malabar Cancer Centre, Kerala | 2013 – 2014
Education
DM – Medical Oncology
Tata Memorial Hospital | 2010 – 2013
MD
Postgraduate Institute of Medical Education and Research | 2006 – 2009
MBBS
Seth GS Medical College & KEM Hospital | 2000 – 2006
• Member & Secretary – West Zone, Indian Society of Medical and Pediatric Oncology
• Member – Indian Cooperative Oncology Network
• Member – American Society of Clinical Oncology
Professional / Research Awards
● Centre of Excellence Award for Cell & Gene Therapy (2024)
● Shri Vijay Batra Research Foundation (Adley Group) Award (2022)
● FHNO Best Paper Award (2019)
● ISNO Best Paper (Oral) (2018)
● ISNO Best Paper (Poster) (2017)
● ISMPO Best Paper – Kala Venkat Award (2016)
● ICON Best Geriatric Case Award (2014)
● Best of ASCO India Award (2014)
● ISO Best Paper Award – ICC (2013)
● Best Paper (Oral) – ISMPO Conference, Vizag (2012)
● Best Poster Award – ISO Conference, Bhubaneswar (2011)
Academic Distinctions
● Gold Medal – First Rank in Medical Oncology (2013)
● Kataria Gold Medal – Best Postgraduate Student (2009)
● Bruce Davis Gold Medal in Palliative Medicine (2007)
MBBS Academic Awards
● Dr. G. W. Kane Memorial Prize – Surgery (2004)
● Dr. R. H. Karmarkar Gold Medal – General Surgery (2004)
● Dr. N. D. Patel Medicine Prize – Medicine (2004)
● H. Sir Jaswant Singhji Limbdi Prize – 3rd MBBS Aggregate (2004)
● Dr. L. H. Hiranandani Prize – ENT (2003)
● Dr. V. G. Rao 1st Prize – PSM (2003)
Grants, Fellowships & Travel Awards
● ESMO Asia Travel Grant (2016, 2018)
● ACORD Fellowship, Australia (2012)
● ASCO IDEA Award (2014)
Dr. Patil has played a key role in conceptualizing and contributing to numerous publications for development of metronomic, targeted therapies, immunotherapy, geriatric oncology and precision medicine. His impressive research accolades include pioneering research publications that have transformed treatment paradigms, development of new and affordable treatments which provide rays of hope for millions of patients across the globe.
● MANTHAN – AI R&D Leadership Symposium (2026)
● Nepal Cancer Foundation & Purbanchal Cancer Hospital Oration (2025) – Cellular Therapies for Solid Cancer
● ASCO Annual Conference – Oral Presentations (2018, 2020, 2022, 2024)
● ICON Oration (2022) – Geeta Rameshchandra Gandhi Oration
Publications:
Dr. (Prof.) Vijay Patil has authored more than 777 peer-reviewed publications in leading international journals, including the Journal of Clinical Oncology, The Lancet Global Health, Oral Oncology, Cancer, Cancer Cell, and ASCO publications.
Highlights:
1. Noronha V, Patil VM, Menon N, Prabhash K. Change in pattern of failure in head and neck cancer. J Clin Oncol. 2022;40(27):3095–3096. doi:10.1200/JCO.22.00598.
2. Rai RK, Patil VM, Noronha V, Menon NS, Saha S, Alone M, Pai PS, Laskar S, Prabhash K. Real world evidence for use of NACT in locally advanced external auditory canal cancer. J Clin Oncol. 2022;40(16_suppl):e18000. doi:10.1200/JCO.2022.40.16_suppl.e18000.
3. Tongaonkar A, Patil VM, Noronha V, Menon NS, Jogdhankar S, Prabhash K. Real world data of neoadjuvant and adjuvant chemotherapy in head neck osteosarcoma: Experience from a tertiary care center in India. J Clin Oncol. 2022;40(16_suppl):e18012. doi:10.1200/JCO.2022.40.16_suppl.e18012.
4. Singh GK, Prabhash K, Patil VM, Noronha V, Joshi A, Menon NS, Singh P, Qayyumi B, Singh R. Metronomic systemic PCm (paclitaxel, carboplatin + metronomic) neoadjuvant chemotherapy in head and neck cancer. J Clin Oncol. 2022;40(16_suppl):e18073. doi:10.1200/JCO.2022.40.16_suppl.e18073.
5. Kashyap L, Patil VM, Noronha V, Joshi A, et al. Efficacy and safety of neoadjuvant chemotherapy (NACT) with paclitaxel plus carboplatin and oral metronomic chemotherapy (OMCT) in patients with technically unresectable oral squamous cell carcinoma (OSCC). ecancermedicalscience. 2021;15:1325. doi:10.3332/ecancer.2021.1325
6. Patil VM, Noronha V, Menon NS, Shah MJ, Ghosh SL, Budrukkar A, Swain M, Balaji A, Chaukar D, Pai PS, Chaturvedi P, Prabhash K. Long term results of a randomized phase III study of nimotuzumab in combination with concurrent radiotherapy and cisplatin versus radiotherapy and cisplatin alone, in locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol. 2024;42(17_suppl):LBA6092. doi:10.1200/JCO.2024.42.17_suppl.LBA6092
7. Kashyap L, Patil VM, Noronha V, Joshi A, et al. Outcome of neoadjuvant chemotherapy (NACT) with paclitaxel plus carboplatin and oral metronomic chemotherapy (OMCT) in patients with technically unresectable oral cavity squamous cell carcinoma (SCC). ecancermedicalscience. 2021;15:1325. doi:10.3332/ecancer.2021.1325
8. Bhattacharjee A, Noronha V, Patil VM, Abhayankar A, Joshi A, Menon NS, et al. Optimal cumulative cisplatin dose for radio-sensitization in locally advanced head and neck cancer. Journal of Clinical Oncology. 2020;38(15_suppl):e18553. doi:10.1200/JCO.2020.38.15_suppl.e18553.
9. Srinivas S, Noronha V, Patil VM, Joshi A. Hypothyroidism and its impact on outcomes in head and neck cancer. Journal of Clinical Oncology. 2020;38(15_suppl):e24066–e24066. doi:10.1200/JCO.2020.38.15_suppl.e24066.
10. Dhumal SB, Noronha V, Patil VM, Joshi A, Menon NS, Jain P, et al. A phase III randomized clinical trial of diclofenac versus tramadol for mucositis-related pain in head and neck cancer patients undergoing concurrent chemoradiation. Journal of Clinical Oncology. 2020;38(15_suppl):e24124. doi:10.1200/JCO.2020.38.15_suppl.e24124.
11. Rajendra A, Noronha V, Patil VM, Joshi A, Menon NS, Prabhash K. Incidence of 5-fluorouracil related cardiotoxicity in patients with head and neck cancer. Journal of Clinical Oncology. 2020;38(15_suppl):e24123. doi:10.1200/JCO.2020.38.15_suppl.e24123.
12. Singh GK, Swami R, Patil VM, Noronha V, Joshi A, Menon NS, et al. Second malignancy post-chemoradiation in head and neck cancer patients. Journal of Clinical Oncology. 2020;38(15_suppl):e18525. doi:10.1200/JCO.2020.38.15_suppl.e18525.
13. Noronha V, Joshi A, Patil VM, Agrawal JP, Ghosh-Laskar S, Budrukkar A, et al. Once-a-week versus once-every-3-weeks cisplatin chemoradiation for locally advanced head and neck cancer: a phase III randomized noninferiority trial. Journal of Clinical Oncology. 2018;36(11):1064–1072. doi:10.1200/JCO.2017.74.9457.
14. Noronha V, Joshi A, Patil VM, Agrawal JP. Phase III randomized trial comparing weekly versus three-weekly (W3W) cisplatin in patients receiving chemoradiation for locally advanced head and neck cancer. Journal of Clinical Oncology. 2017;35(15_suppl):6007. doi:10.1200/JCO.2017.35.15_suppl.6007.
15. Sharma V, Patil VM, Noronha V, Joshi A, et al. Toxicity, tolerance and outcomes of carboplatin based CTRT (concurrent chemoradiation) in head and neck cancers in patients who were not fit for cisplatin based CTRT. Journal of Clinical Oncology. 2016;34(15_suppl):e17539. doi:10.1200/JCO.2016.34.15_suppl.e17539.
16. Patil VM, Kane S, Noronha V, Joshi A, et al. NACT in locally advanced oral cancers: does HPV make a difference? Journal of Clinical Oncology. 2015;33(15_suppl):e17068. doi:10.1200/jco.2015.33.15_suppl.e17068.
17. Prabhash K, Patil VM, Noronha V, Dhumal S, Joshi A. Compliance to NACT in T4 oral cancers: the place, person, socioeconomic status or assistance. Journal of Clinical Oncology. 2015;33(15_suppl):e17534. doi:10.1200/jco.2015.33.15_suppl.e17534.
18. Singhal P, Patil VM, Muckaden MA, Deodhar J, Salins N, Noronha V, et al. Effect of early integration of specialized palliative care into standard oncologic treatment on the quality of life of patients with advanced head and neck cancers: a phase III randomized controlled trial. Journal of Clinical Oncology. 2020;38(15_suppl):e24131. doi:10.1200/JCO.2020.38.15_suppl.e24131.
19. Menon NS, Noronha V, Joshi A, Patil VM, Bhattacharjee A, Kalra D, et al. Quality of life in patients with locally advanced head and neck cancer undergoing chemoradiation with once-a-week versus once-every-three-weeks cisplatin. Journal of Clinical Oncology. 2020;38(15_suppl):12092. doi:10.1200/JCO.2020.38.15_suppl.12092.
20. Menon NS, Noronha V, Patil VM, Dhumal SB, Joshi A, Sable N, et al. Low-cost oral metronomic versus intravenous chemotherapy in recurrent, inoperable and metastatic head and neck cancer: phase III Metro-CIS study. Journal of Clinical Oncology. 2020;38(15_suppl):6506. doi:10.1200/JCO.2020.38.15_suppl.6506.
21. Mahajan A, Chand A, Patil VM, Noronha V, Joshi A, Sable N, et al. Prognostic value of radiological extranodal extension detected by computed tomography for predicting outcomes in head and neck squamous cell cancer patients treated with radical chemoradiotherapy. Journal of Clinical Oncology. 2020;38(15_suppl):6560. doi:10.1200/JCO.2020.38.15_suppl.6560.
22. Chaukar D, Prabhash K, Rane P, Patil VM, Thiagarajan S, Ghosh-Laskar S, et al. Prospective phase II open-label randomized controlled trial to compare mandibular preservation in upfront surgery with neoadjuvant chemotherapy followed by surgery in operable oral cavity cancer. Journal of Clinical Oncology. 2022;40(3):272–281. doi:10.1200/JCO.21.00179.
23. D’souza H, Noronha V, Patil VM, Joshi A, Menon NS, Prabhash K. Aprepitant in weekly cisplatin with radiation in head and neck cancer: is it required? Journal of Clinical Oncology. 2020;38(15_suppl):e24122. doi:10.1200/JCO.2020.38.15_suppl.e24122.
24. Kashyap L, Patil VM, Dhumal SB, Noronha V, Joshi A, Menon NS, et al. Efficacy and safety of neoadjuvant chemotherapy (NACT) with paclitaxel plus carboplatin and oral metronomic chemotherapy (OMCT) in patients with technically unresectable oral cavity squamous cell carcinoma (SCC). Journal of Clinical Oncology. 2020;38(15_suppl):e18550. doi:10.1200/JCO.2020.38.15_suppl.e18550.
25. Patil VM, Noronha V, Joshi A, Dhumal SB, et al. Phase I/II study of palliative triple metronomic chemotherapy in platinum-refractory/early-failure oral cancer. Journal of Clinical Oncology. 2019;37(32):1076. doi:10.1200/JCO.19.01076.
26. Chakraborty S, Patil VM. Does DeCIDE give a decisive answer against induction chemotherapy in head and neck cancers? Journal of Clinical Oncology. 2015;33(8):967. doi:10.1200/JCO.2014.58.3914.
27. Patil VM, Noronha V, Banavali SD, Joshi A, Dhumal S, Arya S, et al. A phase II study comparing metronomic chemotherapy with chemotherapy (single-agent cisplatin) in patients with metastatic, relapsed, or inoperable squamous cell carcinoma of head and neck. Journal of Clinical Oncology. 2014;32(15_suppl):6017. doi:10.1200/jco.2014.32.15_suppl.6017.
28. Rath S, Patil VM, Noronha V, Joshi A, Bhosale BB, Punatar S, et al. Epidemiology of oral cancers referred for NACT, the demographics, clinical profile, and organ functions. J Clin Oncol. 2013;31(15_suppl):e12520. doi:10.1200/jco.2013.31.15_suppl.e12520.
29. Noronha V, Patil VM, Joshi A, Juvekar S. Are three drugs better than two and does docetaxel trump paclitaxel in induction therapy for locally advanced oral cavity cancers? J Clin Oncol. 2013;31(15_suppl):6085-6085. doi:10.1200/jco.2013.31.15_suppl.6085
30. Poladia B, Patil VM, Noronha V, Joshi A, et al. Acute toxicity of neoadjuvant chemotherapy in oral cavity cancers: Can it be predicted? J Clin Oncol. 2013;31(15_suppl):e17027. doi:10.1200/jco.2013.31.15_suppl.e17027.
31. Patil V, Prabhash K, Noronha V, Joshi A, Muddu V, Chauhan B, et al. Neoadjuvant chemotherapy followed by definitive local treatment in locally advanced carcinoma maxillary sinus. J Clin Oncol. 2012;30(15_suppl):5585. doi:10.1200/jco.2012.30.15_suppl.5585.
32. Prabhash K, Noronha V, Joshi A, Patil V, Juvekar S, Muddu V. Palliative chemotherapy in head and neck cancers: A tertiary care center experience with weekly paclitaxel and cetuximab. J Clin Oncol. 2012;30(15_suppl):e16028. doi:10.1200/jco.2012.30.15_suppl.e16028.
33. Nair SV, Joshi A, Patil VM, Noronha V, Sable N, Mahajan A, et al. A phase II randomized control trial of erlotinib in combination with celecoxib in patients with operable oral squamous cell carcinoma (OSCC): Erlo-Xib study. J Clin Oncol. 2019;37(15_suppl):6054. doi:10.1200/JCO.2019.37.15_suppl.6054.
34. Borges FC, van der Graaf WT, Saesen R, Aebi S, Amariuței AE, Bekelman JE, et al. Defining the role of pragmatic clinical trials in cancer clinical research: outcomes of a collaborative workshop hosted by the European Organisation for Research and Treatment of Cancer. Lancet Oncol. 2025;26(5):E253-E263.
35. Naidu PD, Patil VM, Noronha V, Nawale K, et al. Five years survival outcomes of head and neck cancer patients treated with palliative metronomic chemotherapy. J Clin Oncol. 2022;40(16_suppl):e18009-e18009. doi:10.1200/JCO.2022.40.16_suppl.e18009.
36. Ravikrishna M, Abraham G, Patil VM, Bhattacharjee A, Noronha V, Menon N, et al. Checkpoint inhibitor accessibility in 15,000+ Indian patients. J Clin Oncol. 2022;40(16_suppl):9012. doi:10.1200/JCO.2022.40.16_suppl.9012.
37. Agarwala V, Patil VM, Noronha V, Joshi A, Chougule A, Trivedi V, et al. Quality of life analysis of pemetrexed versus erlotinib maintenance in EGFR mutation negative advanced non small cell lung cancer. J Clin Oncol. 2018;36(15_suppl):9024. doi:10.1200/JCO.2018.36.15_suppl.9024.
38. Mahajan A, Prabhash K, Noronha V, Joshi A, Patil VM, Agarwal S, et al. Impact of imaging based sarcopenia and modified advanced lung cancer inflammation index (mALI) on clinical outcomes in advanced NSCLC: A occult killer and a prognostic biomarker. J Clin Oncol. 2018;36(15_suppl):e24166. doi:10.1200/JCO.2018.36.15_suppl.e24166.
39. Sekar A, Rajendra A, Noronha V, Mokal S, Patil VM, Menon N, et al. The epidemiological trend of esophageal cancer in Mumbai, India over the past two decades. J Clin Oncol. 2021;39(15_suppl):e16095. doi:10.1200/JCO.2021.39.15_suppl.e16095.
40. Kumar SK, Nandhana R, Dhanawat A, Noronha V, Patil VM, Menon N, et al. Pulmonary sarcomatoid carcinoma: Retrospective analysis from a single center. J Clin Oncol. 2021;39(15_suppl):e21188. doi:10.1200/JCO.2021.39.15_suppl.e21188.
41. Noronha V, Ramaswamy A, Patil VM, Gattani S, Menon N, Mahajan S, et al. Impact of the geriatric assessment on clinical treatment decision in older Indian persons with cancer. J Clin Oncol. 2021;39(15_suppl):e24015. doi:10.1200/JCO.2021.39.15_suppl.e24015.
42. Noronha V, Patil VM, Joshi A, Menon NS, Goud S, More S, et al. A randomized clinical trial evaluating the efficacy and safety of the addition of oral metronomic chemotherapy after completion of standard chemoradiation versus observation in patients with locally advanced esophageal and gastroesophageal junction squamous cell carcinoma. J Clin Oncol. 2021;39(3_suppl):163. doi:10.1200/JCO.2021.39.3_suppl.163.
43. Patil V, Noronha V, Vallathol DH, Menon N, Mahajan A, Janu A, et al. Leptomeningeal metastasis from non-small cell lung cancer—a post-hoc analysis from four randomised clinical trials. ecancermedicalscience. 2022;16:1414. doi:10.3332/ecancer.2022.1414.
44. Noronha V, Patil VM, Joshi A, Menon N, Chougule A, Prabhash K. Reply to T. Tanaka et al and F. Liang. J Clin Oncol. 2020;38(8):844-846. doi:10.1200/JCO.19.02974.
45. Prabhash K, Parikh PM, Rajappa SJ, Noronha V, Joshi A, Aggarwal S, et al. EGFR testing scenario across 111 centres in India: A questionnaire-based survey. J Clin Oncol. 2017;35(15_suppl):e13111. doi:10.1200/JCO.2017.35.15_suppl.e13111.
46. Zanwar S, Noronha V, Joshi A, Patil VM, Chougule A, Janu A, et al. Feasibility and outcome of repeat biopsy upon progression on tyrosine kinase inhibitors in patients with EGFR mutation positive adenocarcinoma of lung-an Indian tertiary cancer centre experience. J Clin Oncol. 2017;35(15_suppl):e20628. doi:10.1200/JCO.2017.35.15_suppl.e20628.
47. Patil VM, Noronha V, Joshi A, Ghosh J, Bhattacharjee A, Prabhash K. A cross sectional retrospective study regarding patients and their physician willingness to wait for driver mutation report in NSCLC. J Clin Oncol. 2015;33(15_suppl):e17532. doi:10.1200/jco.2015.33.15_suppl.e17532.
48. Noronha V, Patil V, Joshi A, Muddu V, Prabhash K. Baby-step chemotherapy as a way to deliver chemotherapy in poor PS small cell lung cancer. J Clin Oncol. 2012;30(15_suppl):e17500. doi:10.1200/jco.2012.30.15_suppl.e17500.
49. Noronha V, Patil VM, Joshi A, Menon N, Chougule A, Mahajan A, et al. Gefitinib versus gefitinib plus pemetrexed and carboplatin chemotherapy in EGFR-mutated lung cancer. J Clin Oncol. 2020;38(2):124-136. doi:10.1200/JCO.19.01154.
50. Noronha V, Joshi A, Patil VM, Chougule A, Mahajan A, Janu A, et al. Phase III randomized trial comparing gefitinib to gefitinib with pemetrexed-carboplatin chemotherapy in patients with advanced untreated EGFR mutant non-small cell lung cancer (gef vs gef+C). J Clin Oncol. 2019;37(15_suppl):9001. doi:10.1200/JCO.2019.37.15_suppl.9001.
51. Shah D, Menon N, Puranik A, Choudhary A, Patil VM, et al. Efficacy of gemcitabine in recurrent meningioma: A phase II study. J Clin Oncol. 2022;40(16_suppl):e14044-e14044. doi:10.1200/JCO.2022.40.16_suppl.e14044.
52. Dhanawat A, Noronha V, Ramaswamy A, Gattani S, Castelino R, Dhekale R, et al. The prevalence of cognitive impairment in older Indian persons with cancer and brain metastases. ecancermedicalscience. 2022;16:1372. doi:10.3332/ecancer.2022.1372.
53. Moitra P, Chatterjee A, Kota PK, Kowtal P, Dasgupta A, Sastri J, et al. MGMT gene polymorphisms in patients with severe hematological toxicity treated with temozolomide for adult diffuse gliomas: Results from a tertiary-care comprehensive cancer center. J Clin Oncol. 2021;39(15_suppl):e14032. doi:10.1200/JCO.2021.39.15_suppl.e14032.
54. Singh GK, Dsouza H, Srinivas J, Vallathol DP, Boppana M, Rajpurohit A, et al. Safety and efficacy of bevacizumab biosimilar in glioma. J Clin Oncol. 2020;38(15_suppl):e14541. doi:10.1200/JCO.2020.38.15_suppl.e14541.
55. Rao AR, Ramaswamy A, Kumar S, Gattani S, Dhekale R, Krishnamurthy J, et al. Prevalence and outcomes of frailty in older patients with cancer: A prospective study from geriatric oncology clinic. J Clin Oncol. 2022;40(16_suppl):e24011. doi:10.1200/JCO.2022.40.16_suppl.e24011.
56. Gupta K, Noronha V, Joshi A, Patil V, Parthiban S, Bollam R, et al. Immunotherapy in advanced cancers and predictor factors for outcome: An Indian experience. J Clin Oncol. 2018;36(15_suppl):e15065. doi:10.1200/JCO.2018.36.15_suppl.e15065.
57. Shah MJ, Mokal S, Gattani S, Ramaswamy A, Joshi A, Patil VM, et al. The use of G8 and VES13 as screening and prognostic tools in older Indian patients with cancer. J Clin Oncol. 2021;39(15_suppl):e24024. doi:10.1200/JCO.2021.39.15_suppl.e24024.
58. Gattani S, Noronha V, Ramaswamy A, Castelino R, Nair V, Krishnamurthy MN, et al. Accuracy of the CARG chemotherapy toxicity risk prediction tool in older Indian patients with cancer. J Clin Oncol. 2021;39(15_suppl):e24023-e24023. doi:10.1200/JCO.2021.39.15_suppl.e24023.
59. Kapoor A, Noronha V, Patil VM, Joshi A, Menon NS, Prabhash K. Association of immune-related adverse effects and survival in responders treated with immune checkpoint inhibitors. J Clin Oncol. 2020;38(15_suppl):e15172. doi:10.1200/JCO.2020.38.15_suppl.e15172.
